Investors Purchase High Volume of Ironwood Pharmaceuticals Call Options (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the target of some unusual options trading on Monday. Traders acquired 1,206 call options on the stock. This is an increase of 2,133% compared to the typical volume of 54 call options.

A number of equities analysts have recently issued reports on IRWD shares. ValuEngine lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Cowen set a $12.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, September 13th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $14.50.

IRWD opened at $11.87 on Tuesday. Ironwood Pharmaceuticals has a 52 week low of $7.91 and a 52 week high of $15.21. The business has a 50 day moving average price of $10.58 and a two-hundred day moving average price of $10.15. The company has a market cap of $1.88 billion, a PE ratio of 60.10 and a beta of 1.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, October 31st. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.30. The company had revenue of $131.17 million for the quarter, compared to the consensus estimate of $97.10 million. Ironwood Pharmaceuticals had a negative return on equity of 15.83% and a negative net margin of 9.67%. The company’s revenue was up 99.7% on a year-over-year basis. During the same period last year, the business posted ($0.27) EPS. Analysts predict that Ironwood Pharmaceuticals will post 0.49 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brown Capital Management LLC grew its position in Ironwood Pharmaceuticals by 19.4% in the 2nd quarter. Brown Capital Management LLC now owns 12,329,890 shares of the biotechnology company’s stock valued at $134,889,000 after buying an additional 2,003,252 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 5,744.4% in the 3rd quarter. Millennium Management LLC now owns 1,031,298 shares of the biotechnology company’s stock worth $8,853,000 after acquiring an additional 1,013,652 shares during the period. Nuveen Asset Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at about $10,126,000. Janus Henderson Group PLC boosted its holdings in shares of Ironwood Pharmaceuticals by 12.8% in the second quarter. Janus Henderson Group PLC now owns 7,505,293 shares of the biotechnology company’s stock valued at $82,108,000 after acquiring an additional 852,356 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 15,606,157 shares of the biotechnology company’s stock valued at $170,730,000 after acquiring an additional 664,893 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Further Reading: How Do You Make Money With Penny Stocks?

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply